Imoxat
imidacloprid / moxidectin
Table of contents
Overview
Imoxat is a veterinary medicine used on cats, ferrets and dogs suffering from, or at risk of, mixed parasitic infections (caused by several different types of parasites). The medicine is used:
- to treat and prevent flea infestations in cats, dogs and ferrets;
- to treat ear mite infestations in cats and dogs;
- to treat skin diseases in dogs caused by parasitic mites (sarcoptic mange and demodicosis);
- to treat skin disease in cats caused by a parasitic mite (notoedric mange);
- to treat and prevent lungworm infection in cats and dogs;
- to treat eyeworm disease in cats and dogs;
- to treat infections with gastrointestinal nematodes (gut worms) in cats and dogs;
- to treat biting lice infestation in dogs;
- to prevent heartworm (Dirofilaria immitis) disease in cats, dogs and ferrets;
- to treat circulating Dirofilaria immitis microfilariae in dogs;
- to treat and prevent cutaneous dirofilariosis (skin infection with Dirofilaria repens) in dogs;
- to reduce circulating Dirofilaria repens microfilariae in dogs;
- to prevent and treat French heartworm (Angiostrongylus vasorum) infection in dogs;
- to prevent spirocercosis (a worm infection affecting the gullet) in dogs.
Imoxat can be used as part of a treatment strategy for flea allergy dermatitis in cats and dogs.
It contains the active substances imidacloprid and moxidectin.
Imoxat is a ‘generic medicine’. This means that Imoxat contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the European Union (EU) called Advocate.
Authorisation details
| Product details | |
|---|---|
| Name |
Imoxat
|
| Agency product number |
EMEA/V/C/005597
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
|
| Species |
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP54AB52
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Chanelle Pharmaceuticals Manufacturing Ltd
|
| Date of issue of marketing authorisation valid throughout the European Union |
07/12/2021
|
| Contact address |
Dublin Road |
Product information
Imoxat - EMEA/V/C/005597 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For cats suffering from, or at risk from, mixed parasitic infections: • the treatment of ear mite infestation (Otodectes cynotis), • the treatment of notoedric mange (Notoedres cati), • the treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults), • the prevention of lungworm disease (L3/L4 larvae of Aelurostrongylus abstrusus), • the treatment of the lungworm Aelurostrongylus abstrusus (adults), • the treatment of the eye worm Thelazia callipaeda (adults), • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis), • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme). The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
For ferrets suffering from, or at risk from, mixed parasitic infections: • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis).
For dogs suffering from, or at risk from, mixed parasitic infections: • the treatment and prevention of flea infestation (Ctenocephalides felis), • the treatment of biting lice (Trichodectes canis), • the treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis), • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis), • the treatment of circulating microfilariae (Dirofilaria immitis), • the treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens) • the prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens), • the reduction of circulating microfilariae (Dirofilaria repens), • the prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum), • the treatment of Angiostrongylus vasorum and Crenosoma vulpis, • the prevention of spirocercosis (Spirocerca lupi), • the treatment of Eucoleus (syn. Capillaria) boehmi (adults), • the treatment of the eye worm Thelazia callipaeda (adults), • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis). The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD). |